"Indazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D007191
|
MeSH Number(s) |
D03.383.129.539.487 D03.633.100.449
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indazoles".
Below are MeSH descriptors whose meaning is more specific than "Indazoles".
This graph shows the total number of publications written about "Indazoles" by people in this website by year, and whether "Indazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1997 | 0 | 1 | 1 |
2001 | 2 | 0 | 2 |
2002 | 1 | 0 | 1 |
2003 | 0 | 1 | 1 |
2004 | 0 | 2 | 2 |
2005 | 2 | 0 | 2 |
2007 | 2 | 0 | 2 |
2008 | 1 | 1 | 2 |
2009 | 2 | 1 | 3 |
2010 | 0 | 2 | 2 |
2011 | 3 | 2 | 5 |
2012 | 2 | 2 | 4 |
2013 | 5 | 5 | 10 |
2014 | 7 | 4 | 11 |
2015 | 3 | 11 | 14 |
2016 | 5 | 4 | 9 |
2017 | 2 | 13 | 15 |
2018 | 6 | 7 | 13 |
2019 | 3 | 8 | 11 |
2020 | 3 | 7 | 10 |
2021 | 2 | 3 | 5 |
2022 | 0 | 5 | 5 |
2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Indazoles" by people in Profiles.
-
Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032). Gynecol Oncol. 2023 Nov; 178:161-169.
-
Association of nivolumab and niraparib in the management of neuroendocrine cancer of the cervix. Int J Gynecol Cancer. 2023 04 03; 33(4):623-627.
-
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG). Neuro Oncol. 2022 10 03; 24(10):1776-1789.
-
OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022 10 01; 128(19):3516-3522.
-
Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. J Biol Chem. 2022 08; 298(8):102226.
-
Efficacy and Safety of TRC105 Plus Pazopanib vs Pazopanib Alone for Treatment of Patients With Advanced Angiosarcoma: A Randomized Clinical Trial. JAMA Oncol. 2022 05 01; 8(5):740-747.
-
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2022 03; 23(3):362-373.
-
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer. 2022 02; 126(3):514-520.
-
Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment. Cancer Chemother Pharmacol. 2021 11; 88(5):825-836.
-
Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohorts A, G, H and I of IVY Phase I study. Int J Cancer. 2021 07 15; 149(2):403-408.